Figure 2. Kaplan-Meier Curves of Disease-Free Survival.

A, For all patients, those in the epirubicin plus paclitaxel (EP) group had 89 events; those in the epirubicin and cyclophosphamide followed by paclitaxel (EC-P) group, 100 events. B, For patients with luminal A tumors, patients in the EP group had 21 events; those in the EC-P group, 19 events. C, For patients with luminal B tumors, patients in the EP group had 51 events; those in the EC-P group, 71 events. HR indicates hazard ratio.